

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
AEGERION PHARMACEUTICALS, INC.		07/02/2009	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.		
<b>Street Address:</b>	400 Hamilton Avenue		
<b>Internal Address:</b>	Suite 310		
<b>City:</b>	Palo Alto		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94301		
<b>Entity Type:</b>	CORPORATION: MARYLAND		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
Registration Number:	3300046	AEGERION	
Registration Number:	3448427	AEGERION PHARMACEUTICALS, INC.	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(858)550-6420		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	858-550-6403		
<b>Email:</b>	erin.obrien@cooley.com		
<b>Correspondent Name:</b>	Erin O'Brien		
<b>Address Line 1:</b>	c/o Cooley Godward Kronish LLP		
<b>Address Line 2:</b>	4401 Eastgate Mall		
<b>Address Line 4:</b>	San Diego, CALIFORNIA 92121		
<b>ATTORNEY DOCKET NUMBER:</b>	305866-133 AEGERION		
<b>NAME OF SUBMITTER:</b>	Erin O'Brien		

CH \$65.00 3300046

Signature:	/Erin O'Brien/
Date:	07/06/2009
<p>Total Attachments: 19</p> <p>source=Aegerion signed IPSA#page1.tif source=Aegerion signed IPSA#page2.tif source=Aegerion signed IPSA#page3.tif source=Aegerion signed IPSA#page4.tif source=Aegerion signed IPSA#page5.tif source=Aegerion signed IPSA#page6.tif source=Aegerion signed IPSA#page7.tif source=Aegerion signed IPSA#page8.tif source=Aegerion signed IPSA#page9.tif source=Aegerion signed IPSA#page10.tif source=Aegerion signed IPSA#page11.tif source=Aegerion signed IPSA#page12.tif source=Aegerion signed IPSA#page13.tif source=Aegerion signed IPSA#page14.tif source=Aegerion signed IPSA#page15.tif source=Aegerion signed IPSA#page16.tif source=Aegerion signed IPSA#page17.tif source=Aegerion signed IPSA#page18.tif source=Aegerion signed IPSA#page19.tif</p>	

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of July 2, 2009 by and between HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation ("Lender") and AGERION PHARMACEUTICALS, INC., a Delaware corporation ("Grantor").

### RECITALS

Lender and Grantor are parties to a Loan and Security Agreement dated as of March 20, 2007 (as amended from time to time, the "Loan Agreement"). Capitalized terms used herein have the meaning assigned in the Loan Agreement. In connection with a Second Amendment to Loan and Security Agreement of even date, Grantor has granted to Lender a security interest in Grantor's intellectual property.

NOW, THEREFORE, Grantor agrees as follows:

### AGREEMENT

To secure performance of Grantor's obligations under the Loan Agreement, Grantor grants to Lender a security interest in all of Grantor's right, title and interest in Grantor's intellectual property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits). Grantor authorizes Lender to file such amendment to financing statement and this Intellectual Property Security Agreement as Lender deems appropriate to evidence this grant.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed as of the first date written above.

Address of Borrower:

1140 Route 22 East  
Suite 304  
Bridgewater, NJ 08807  
Attn: William H. Lewis

**AGERION PHARMACEUTICALS, INC.**

By: 

Title: \_\_\_\_\_

Address of Lender:

400 Hamilton Ave., Suite 30  
Palo Alto, CA 94301  
Attn: Legal Dept. and Bryan Jadot

**HERCULES TECHNOLOGY GROWTH CAPITAL,  
INC.**

By: \_\_\_\_\_

Title: \_\_\_\_\_

**INTELLECTUAL PROPERTY SECURITY AGREEMENT**

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of July 2, 2009 by and between HERCULES TECHNOLOGY GROWTH CAPITAL, INC., a Maryland corporation ("Lender") and AEGERION PHARMACEUTICALS, INC., a Delaware corporation ("Grantor").

**RECITALS**

Lender and Grantor are parties to a Loan and Security Agreement dated as of March 20, 2007 (as amended from time to time, the "Loan Agreement"). Capitalized terms used herein have the meaning assigned in the Loan Agreement. In connection with a Second Amendment to Loan and Security Agreement of even date, Grantor has granted to Lender a security interest in Grantor's intellectual property.

NOW, THEREFORE, Grantor agrees as follows:

**AGREEMENT**

To secure performance of Grantor's obligations under the Loan Agreement, Grantor grants to Lender a security interest in all of Grantor's right, title and interest in Grantor's intellectual property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits). Grantor authorizes Lender to file such amendment to financing statement and this Intellectual Property Security Agreement as Lender deems appropriate to evidence this grant.

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed as of the first date written above.

Address of Borrower:

1140 Route 22 East  
Suite 304  
Bridgewater, NJ 08807  
Attn: William H. Lewis

**AEGERION PHARMACEUTICALS, INC.**

By: \_\_\_\_\_

Title: \_\_\_\_\_

Address of Lender:

400 Hamilton Ave., Suite 300 <sup>(KNM)</sup>  
Palo Alto, CA 94301  
Attn: Legal Dept. and Bryan Jadot

**HERCULES TECHNOLOGY GROWTH CAPITAL,  
INC.**

By: 

Title: K. Nicholas Martitsch  
Associate General Counsel

**EXHIBIT A  
COPYRIGHTS**

<b>TITLE</b>	<b>REGISTRATION NUMBER</b>	<b>REGISTRATION DATE</b>

**EXHIBIT B**  
**PATENTS/PATENT APPLICATIONS**

Aegerion Pharmaceuticals Patents-Owned and Licensed

Application #:	Filing Date:	Country	Application Title:	Patent #:	Issue Date:
60788,616	03-Apr-2006	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
60727664	18-Oct-2005	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2006304689	18-Oct-2006	AU	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2626461	18-Oct-2006	CA	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
06836404.1	18-Oct-2006	EP	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2008-536810	18-Oct-2006	JP	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
12/090539	27-Jun-2008	US	COMPOSITIONS AND METHODS FOR LOWERING SERUM LIPID LEVELS		
2006304531	18-Oct-2006	AU	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2626422	18-Oct-2006	CA	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
06817090.1	18-Oct-2006	EP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2008-536750	18-Oct-2006	JP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
12/197621	25-Aug-2008	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
US06/40637	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2006304541	18-Oct-2006	AU	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2626441	18-Oct-2006	CA	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
06817093.5	18-Oct-2006	EP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		
2008-536751	18-Oct-2006	JP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL		

Aegerion Pharmaceuticals Patents-Owned and Licensed

11/582833	18-Oct-2006	US	HYPERLIPIDEMIA IN A MAMMAL
US06/40640	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL
06817092.7	18-Oct-2006	EP	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL
11/582876	18-Oct-2006	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL
US06/40639	18-Oct-2006	WO	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL
60/876280	21-Dec-2006	US	METHODS FOR TREATING OBESITY
11/962383	21-Dec-2007	US	METHODS FOR TREATING OBESITY
US07/26300	21-Dec-2007	PCT	METHODS FOR TREATING OBESITY
2007338625	21-Dec-2007	AU	METHODS FOR TREATING OBESITY
	21-Dec-2007	CA	METHODS FOR TREATING OBESITY
	21-Dec-2007	EP	METHODS FOR TREATING OBESITY
	21-Dec-2007	JP	METHODS FOR TREATING OBESITY
60/909833	03-Apr-2007	US	METHODS FOR TREATING HEPATITIS C
US08/58992	01-Apr-2008	PCT	METHODS FOR TREATING HEPATITIS
61/144542	14-Jan-2009	US	METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN AN MAMMAL
61/144544	14-Jan-2009	US	METHODS FOR TREATING OBESITY AND DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL



Aegerion Pharmaceuticals Patents-Owned and Licensed

Patent Applications licensed from UPenn

US06/40953	18-Oct-2006	WO	METHODS AND COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL	
2005221656	07-Mar-2005	AU	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
2,558,766	07-Mar-2005	CA	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
05724887.4	07-Mar-2005	EP	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
	07-Mar-2005	IN	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
2007-502093	07-Mar-2005	JP	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
10-2006-7020836	07-Mar-2005	KR	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
549721	07-Mar-2005	NZ	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
10/591923	05-Sep-2006	US	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	
60/550915	05-Mar-2004	US	METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS	

Aegerion Pharmaceuticals Patents-Owned and Licensed

US05/007435	07-Mar-2005	WO		DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS			
				METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS			

Patents/Applications Licensed from Bayer

333677	28-Sep-1995	AR		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	256140M		31-Oct-2005
95114877.4	21-Sep-1995	AT		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831		10-Apr-1996
32920/95	27-Sep-1995	AU		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	700609		22-Apr-1999
95114877.4	21-Sep-1995	BE		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831		10-Apr-1996
950624	04-Oct-1995	BY		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5422		24-Apr-2003
2159546	29-Sep-1995	CA		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES			
95114877.4	21-Sep-1995	CH		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831		10-Apr-1996
1513-95	02-Oct-1995	CL		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	40,031		19-Jul-1999
95117117.8	04-Oct-1995	CN		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	52189		10-Dec-1999
98126085.3	04-Oct-1995	CN		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	188667		05-Jan-2005
2567-95	03-Oct-1995	CZ		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	291348		11-Dec-2002
95114877.4	21-Sep-1995	DE		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	59510839.3		10-Apr-1996
95114877.4	21-Sep-1995	DK		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831		10-Apr-1996
5232	26-Sep-1995	DO		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5232		11-Apr-1996
0116-95	02-Oct-1995	DZ		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES			
P9500071	03-Oct-1995	EE		CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	03527		15-Oct-2001

Aegerion Pharmaceuticals Patents-Owned and Licensed

95114877.4	21-Sep-1995	EP	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	ES	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
954681	03-Oct-1995	FI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	113048	27-Feb-2004
20002693	08-Dec-2000	FI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	108791	28-Mar-2002
95114877.4	21-Sep-1995	FR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	GB	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	GR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
98104346.6	19-May-1998	HK	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	HK1005139	21-May-2004
9160/95	29-Sep-1995	HIN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	3769181	14-Apr-2000
P950505A	27-Sep-1995	HIR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	P950505	03-Apr-2002
9502891	03-Oct-1995	HU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
P952018	04-Oct-1995	ID	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	ID0009015	21-Oct-2002
95114877.4	21-Sep-1995	IE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
115493	02-Oct-1995	IL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	115493	30-Jan-2000
129641	02-Oct-1995	IL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	129641	30-Jan-2000
95114877.4	21-Sep-1995	IT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
279664/95	03-Oct-1995	JP	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
10-1995-33651	02-Oct-1995	KR	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	10-355986	26-Sep-2002
95114877.4	21-Sep-1995	LT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	LU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95114877.4	21-Sep-1995	LV	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
24026	02-Oct-1995	MA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	23682	01-Jul-1996

Aegerion Pharmaceuticals Patents-Owned and Licensed

95114877.4	21-Sep-1995	MC	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
954196	03-Oct-1995	MX	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	193845	
9502964	04-Oct-1995	MY	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	117282-A	30-Jun-2004
95114877.4	21-Sep-1995	NL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
953930	03-Oct-1995	NO	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	305365	18-May-1999
280130	29-Sep-1995	NZ	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	280130	
51415	03-Oct-1995	PH	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	31400	29-Oct-1998
310756	03-Oct-1995	PL	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	183154	09-Oct-2001
95114877.4	21-Sep-1995	PT	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
95117070	03-Oct-1995	RU	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	2157803	20-Oct-2000
95114877.4	21-Sep-1995	SE	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
9501478-3	03-Oct-1995	SG	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	63528	30-Mar-1999
95114877.4	21-Sep-1995	SI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	705831	10-Apr-1996
1239-95	03-Oct-1995	SK	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	284260	05-Oct-2004
62-95	04-Oct-1995	SV	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	154-1-309	11-Sep-2000
28216	02-Oct-1995	TH	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	13768	01-Nov-2002
1323	02-Oct-1995	TI	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
95098	02-Oct-1995	TN	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	17943	
84-110247	02-Oct-1995	TW	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	140388	04-Jan-2002
95104372	03-Oct-1995	UA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	44700	15-Mar-2002
08/535698	28-Sep-1995	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	5,684,014	04-Nov-1997
08/887781	03-Jul-1997	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,245,775	12-Jun-2001

Aegerion Pharmaceuticals Patents-Owned and Licensed

09/313035	17-May-1999	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,265,431	24-Jul-2001
09/734955	11-Dec-2000	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES		
09/814263	21-Mar-2001	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,479,503	12-Nov-2002
10/198315	18-Jul-2002	US	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	6,858,622	22-Feb-2005
95-8297	03-Oct-1995	ZA	CYCLOALKANO-INDOLE AND -AZAINDOLE DERIVATIVES	95-8297	
2413277	08-Jun-2001	CA	USE OF MICROSMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)		
503264-2002	08-Jun-2001	JP	USE OF MICROSMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)		
11/388810	24-Mar-2006	US	USE OF MICROSMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITORS FOR REDUCING THE NUMBER OF POSTPRANDIAL TRIGLYCERIDE-RICH LIPOPROTEIN PARTICLES (PPTRL)		
2201435	01-Apr-1997	CA	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	2201435	12-Dec-2006
97104941.6	24-Mar-1997	DE	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	59710487.5	30-Jul-2003
97104941.6	24-Mar-1997	EP	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND	799829	30-Jul-2003

Aegerion Pharmaceuticals Patents-Owned and Licensed

97104941.6	24-Mar-1997	ES	THEIR ACTIVATED DERIVATIVES PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
97104941.6	24-Mar-1997	FR	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
97104941.6	24-Mar-1997	GB	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
97104941.6	24-Mar-1997	IT	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	799829	30-Jul-2003
96351-97	01-Apr-1997	JP	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	4235268	
97104941.6	24-Mar-1997	SE	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	97104941.6	30-Jul-2003
08/829566	31-Mar-1997	US	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE CYCLOALKANO-INDOL -AND AZAIINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES	5,952,498	14-Sep-1999
09/307980	10-May-1999	US	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE	6,774,236	10-Aug-2004

Aegerion Pharmaceuticals Patents-Owned and Licensed

P000103129	22-Jun-2000	AR	CYCLOALKANO-INDOL -AND AZAINDOL -AND PYRIMIDO [1.2A] INDOLCARBOXYCLIC ACIDS AND THEIR ACTIVATED DERIVATIVES		
1242	08-Jun-2000	BS	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS	1242	29-Jan-2002
2000-100	15-Jun-2000	HIN	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS	4029-431 -VII	18-Oct-2001
505893-2001	13-Jun-2000	JP	COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS		
07733696.4	18-May-2006	EP	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
PCT/GB2007/050275	18-May-2007	WO	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
11/750566	18-May-2007	US	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
200725994	18-May-2007	AU	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
2652751	18-May-2007	CA	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		
510557/09	18-May-2008	JP	PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING SAME		

Patents/Applications licensed from BMS

08/854,311	12-May-1997	US	METHOD FOR LOWERING SERUM LIPID LEVELS EMPLOYING AN MTP INHIBITOR IN COMBINATION WITH ANOTHER CHOLESTEROL LOWERING DRUG	5,883,109	16-Mar-1999
08/486,929	07-Jun-1995	US	MICROSOMAL TRIGLYCERIDE	6,492,365	10-Dec-2002

TRADEMARK

REEL: 004017 FRAME: 0373

Aegerion Pharmaceuticals Patents-Owned and Licensed

199647631	01-Feb-1996	AU	TRANSFER PROTEIN	699865	17-Dec-1998
2,213,466	01-Feb-1996	CA	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD		
96903604.5	01-Feb-1996	DE	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	EP	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	ES	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	FR	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
96903604.5	01-Feb-1996	GB	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
116,917	26-Jan-1996	IL	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	116,917	03-Dec-2000
96903604.5	01-Feb-1996	IT	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	0886637	04-May-2005
525679/96	01-Feb-1996	JP	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	4036244	
08/472,067	06-Jun-1995	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	5,739,135	14-Apr-1998
08/548,811	11-Jan-1996	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	5,712,279	27-Jan-1998
08/898,303	21-Jul-1997	US	INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND METHOD	6,066,650	23-May-2000



Aegerion Pharmaceuticals Patents-Owned and Licensed

Patent Applications licensed from UTexas

US08/51097	15-Jan-2008	PCT	TREATING HEPATITIS C
11/657856	24-Jan-2007	US	TREATING HEPATITIS C

Patent/Patent Applications licensed from Duke

US6207855  
US6359167  
US6488951  
US6583311  
US7015347  
US6459182  
US7049308  
US7259250  
US6538166  
US6887944  
US7030238  
US6472390  
USSN 11/812399  
PCT/US2007/016598

**EXHIBIT C**  
**TRADEMARKS/TRADEMARK APPLICATIONS**

**Client: 121052 Aegerion Pharmaceuticals**

**Trademark**

**AEGERION**

**Country:** Canada

**AEGERION**

**Country:** China (Peoples Republic)

**AEGERION**

**Country:** European Community

**AEGERION**

**Country:** Japan

**AEGERION**

**Country:** United States of America

**AEGERION (logo)**

**Country:** European Community

**AEGERION (logo)**

**Country:** Japan

**AEGERION and (logo)**

**Country:** China (Peoples Republic)

**Application Date  
Registration Date**

11-Dec-2006

12-Dec-2006

12-Dec-2006

12-Dec-2006

11-Dec-2006

27-Apr-2007

12-Jun-2006

25-Sep-2007

12-Dec-2006

12-Dec-2006

11-Dec-2006

27-Apr-2007

12-Dec-2006

**Application No.  
Registration No.**

1327744

-

5547054

5547054

2006-114211

5044877

78906083

3300046

5547062

5547062

2006-114212

5044878

**Status**

Pending

Pending

Registered

Registered

Registered

Registered

Registered

Pending

# Trademark Status Report by Client

Page: 2

	Application Number	App Date
	Registration Number	Reg Date
AEGERION PHARMACEUTICALS, INC. (color logo) <i>Country:</i> United States of America	77283527 3448427	19-Sep-2007 17-Jun-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> Canada	1,388,054	19-Mar-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> China (Peoples Republic)	6,605,387	19-Mar-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> European Community	6765606	19-Mar-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> Hong Kong	301075392 301075392	19-Mar-2008 9-Nov-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> India	1667251	19-Mar-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> Japan	2008-020650	19-Mar-2008
AEGERION PHARMACEUTICALS, INC. (logo) <i>Country:</i> Mexico	921879 1058239	19-Mar-2008 29-Aug-2008

**Client: 121052**      **Aegerion Pharmaceuticals**

**Trademark**

**AEGERION PHARMACEUTICALS, INC. (logo)**  
*Country:* South Africa

**Status**

Pending

**Application Number**  
**Registration Number**

2008/06216

**Application Date**  
**Registration Date**

19-Mar-2008

**AEGERION PHARMACEUTICALS, INC. (logo)**

*Country:* Taiwan

Registered

97012128

1340728

19-Mar-2008